Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). The goal of the study being held in China is to assess the efficacy and safety of parsaclisib in patients having recurrent or refractory follicular lymphoma or marginal zone lymphoma […]
Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular lymphoma (FL). As per the new drug application (NDA) that has been accepted by the FDA, the Massachusetts-based biopharma company is seeking the accelerated approval of the methyltransferase inhibitor for […]
US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL). The late-stage study enrolled 169 subjects in the FLASH clinical trial. This was after Soligenix secured positive interim analysis, which included a prospectively […]
Verastem Oncology has secured orphan drug designation for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), from the US Food and Drug Administration (FDA) for the treatment of T-Cell lymphoma. COPIKTRA has FDA approval for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) following more than two prior therapies. The PI3K also has […]
Pixuvri EMA approval : French pharma company Servier has secured full approval for Pixuvri (pixantrone) from the European Commission (EC) as monotherapy for aggressive non-Hodgkin B-cell lymphoma (NHL) in adult patients whose condition is multiply relapsed or refractory. Pixuvri EMA approval Since 2012, Pixantrone has been available in Europe to patients following conditional approval, which […]
Kite Pharma has clinched the US FDA approval for its Car T therapy Yescarta (axicabtagene ciloleucel) for treating a type of lymphatic cancer in patients who have no more treatment options left and are staring at a dire prognosis.
In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration (FDA) for its chimeric antigen receptor T cell (CAR T) therapy, Yescarta (axicabtagene ciloleucel). This new therapy is now approved for adult patients in the United States with relapsed or refractory […]